Business Wire

Veritas Capital Completes Acquisition of Wood Mackenzie

Share

Veritas Capital (“Veritas”), a leading investor at the intersection of technology and government, today announced that an affiliate of Veritas has completed the purchase of Wood Mackenzie from Verisk (Nasdaq: VRSK).

Wood Mackenzie is a globally recognized industry leader that has been providing quality data, analytics, and insights used to power the energy, renewables, and natural resources industry for nearly 50 years. The Wood Mackenzie Lens© platform enables world class analytics and insights to drive critical decision making for the company’s longstanding clients that operate at the leading edge of the rapidly evolving energy sector. Wood Mackenzie operates at the nexus of current energy industry tailwinds, offering clients leading energy data and analytics with the bold purpose of transforming the way the planet is powered. The acquired company will be led by Mark Brinin, who has been promoted from Co-President to Chief Executive Officer. Joe Levesque has been appointed as President & Chief Operating Officer.

Mark Brinin, Chief Executive Officer for Wood Mackenzie said, “We are excited to embark on the next chapter for Wood Mackenzie in partnership with Veritas. To be returning to our roots as a standalone company and partnering with a firm with Veritas’ track record places us in a unique and enviable peer group. In Veritas, we have found a strategic partner that will enable us to realise greater value for our customers, both in mature markets we have served for the last five decades, as well as in the evolving power and renewables sector which is currently driving the global energy transition.”

Veritas brings deep sector knowledge and operational expertise to Wood Mackenzie. As a premier investor in technology and technology-enabled companies that provide critical products, software, and services to government and commercial customers worldwide, Veritas will assist Wood Mackenzie as it continues to play a critical role in accelerating the global transition to a more sustainable future.

“We are excited to welcome Wood Mackenzie to the Veritas portfolio and partner with the team to drive its next phase of growth,” said Ramzi Musallam, Chief Executive Officer and Managing Partner of Veritas. “Building on its decades of leadership and innovation in the energy industry, Wood Mackenzie is well positioned to expand and enhance the critical insights provided to its growing customer base across the entire energy and renewables value chain.”

Morgan Stanley acted as financial advisors and Davis Polk & Wardwell LLP served as legal counsel to Verisk in connection with the transaction. Gibson, Dunn & Crutcher LLP served as legal counsel to Veritas.

About Veritas Capital
Veritas is a longstanding technology investor with over $40 billion of assets under management and a focus on companies operating at the intersection of technology and government. The firm invests in companies that provide critical products, software, and services, primarily technology and technology-enabled solutions, to government and commercial customers worldwide. Veritas seeks to create value by strategically transforming the companies in which it invests through organic and inorganic means.

Leveraging technology to make a positive impact across vitally important areas, such as healthcare, education, and national security, is core to the firm. Veritas is a proud steward of national assets, improving the quality of healthcare while reducing cost, advancing our educational system, and protecting our nation and allies. For more information, visit www.veritascapital.com.

About Wood Mackenzie
Wood Mackenzie is a trusted source of commercial intelligence for the world's natural resources sector. We empower customers to make better strategic decisions, providing objective analysis and advice on assets, companies and markets. For more information, visit: www.woodmac.com or follow us on Twitter @WoodMackenzie.

WOOD MACKENZIE is a trademark of Wood Mackenzie Limited and is the subject of trademark registrations and/or applications in the European Community, the USA, and other countries around the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA
For Veritas Capital:
FGS Global
VeritasCapital@fgsglobal.com

For Wood Mackenzie:
Sonia Kerr, Director – PR & Internal Communications
+44 330 174 7267
sonia.kerr@woodmac.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mundipharma and Vectura announce plans to reformulate flutiform ® (fluticasone propionate/formoterol fumarate) pressurised metered-dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint16.4.2024 11:00:00 CEST | Press release

Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416962162/en/ The productis an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of a combination product is appropriate, and has been available on the market for more than a decade.3 It currently uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant.3 European Union regulation on these types of gases aims to reduce their use, and therefore their emissions, by two-thirds by 2030.1 Work is already under way to source an alternative

Caranx Medical announces successful world first robotic assisted transcatheter heart valve implantation in an animal16.4.2024 10:30:00 CEST | Press release

Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal. The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Caranx CMO Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team. “This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients' lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx. “This major medical first lies not only in the technical achievement of Caranx Medical's engine

Arthur D. Little Publishes Human After All – Latest Edition of PRISM Magazine16.4.2024 10:00:00 CEST | Press release

Arthur D. Little (ADL) has published Human After All – the latest edition of its strategy and innovation magazine PRISM. As we enter the era of AI, the first edition of 2024 highlights the importance of taking a human-centric approach to business management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416226137/en/ Arthur D. Little has published Human After All – the latest edition of its strategy and innovation magazine PRISM. (Graphic: Business Wire) The magazine features seven key articles: Optimistic global CEOs focus on people and skills in an AI future - Our lead article shares highlights from the ADL 2024 CEO Insights Study, finding that CEOs are increasingly confident of future economic success. The people-centric lab of the future – how technology and AI can play a key role in driving breakthrough innovation by enabling people to become perfect innovators. The future workforce - Recruiting and retaining vital

Magnesium Capital closes oversubscribed inaugural Fund at €135m hard cap16.4.2024 09:32:00 CEST | Press release

Magnesium Capital, the Energy Transition buyout specialist, is delighted to announce the successful close of its inaugural Fund, Magnesium Capital I, at its hard cap of €135m, exceeding the €100m Fund target. The final close occurred less than a year after the Fund’s first close with Magnesium attracting blue-clip institutional investors from the US, Europe and the UK. Magnesium focuses on profitable European companies with proven technologies or tech-enabled services that are positively impacting the decarbonisation of the production, distribution and consumption of energy. The team has been backing the buyouts of such businesses for a number of years on a direct deal basis. Since inception, Magnesium has completed seven platform investments, signed six follow-on acquisitions and exited two investments for 4.2x gross MOIC. The combined impact of these portfolio companies already directly contributes to the avoidance of over 30 million tonnes of CO2 equivalent per annum. Ian Jones, Man

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH00216.4.2024 09:00:00 CEST | Press release

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. MRM Health’s MH002-PC-201 study was a multi-center, open-label clinical trial in 14 acute Pouchitis (PC) patients at multiple clinical sites in Belgium and Italy. The study was designed to evaluate safety (primary objective), initial efficacy, and mechanistic effects of MH002 over 8 weeks. More information about the trial is available at clinicaltrialsregister.eu. The trial met its primary objective with an excellent safety and tolerability at a fixed dose of 400mg per day over 8 weeks’ administration. Treatment-Emergent Adverse Events (TEAE) reported were predominantly mild and unrelated, and there was no evidence of adverse reactions related to MH002. It also demonstrated initial efficacy in clinically relevant parameters,

HiddenA line styled icon from Orion Icon Library.Eye